In vitro evaluations of hexokinase-2 inhibition with 3-bromopyruvate encapsulated in targeted liposomal formulations using 3D spheroid models of tumor aerobic glycolysis
A huge unmet medical need exists in the treatment of ovarian cancer in developing efficacious therapies for the advanced stage patients without the burden of off-target toxicity. This is partly because the current in vitro monolayer cell cultures, which are used for anti-cancer drug development, don...
Published: |
|
---|---|
Online Access: | http://hdl.handle.net/2047/D20213394 |
Similar Items
-
Inhibition of hexokinase-2 with targeted liposomal 3-bromopyruvate in an ovarian tumor spheroid model of aerobic glycolysis
by: Gandham SK, et al.
Published: (2015-07-01) -
Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment
by: Tengjiao Fan, et al.
Published: (2019-03-01) -
3-Bromopyruvate alleviates the development of monocrotaline-induced rat pulmonary arterial hypertension by decreasing aerobic glycolysis, inducing apoptosis, and suppressing inflammation
by: Jie Liu, et al.
Published: (2020-01-01) -
Sinomenine Inhibits Non-Small Cell Lung Cancer via Downregulation of Hexokinases II-Mediated Aerobic Glycolysis
by: Liu W, et al.
Published: (2020-04-01) -
Hexokinase 2 is a Key Mediator of Aerobic Glycolysis Promoting Tumour Growth in Glioblastoma Multiforme
by: Wolf, Amparo
Published: (2010)